Drug Price Trends for FETZIMA ER

Average Pharmacy Cost for FETZIMA ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
FETZIMA ER 120 MG CAPSULE	00456-2212-30	17.58684	EACH	2026-01-02
FETZIMA ER 40 MG CAPSULE	00456-2240-30	17.63040	EACH	2026-01-02
FETZIMA ER 20 MG CAPSULE	00456-2220-30	17.63169	EACH	2026-01-02

Market Analysis and Price Projections for FETZIMA ER

Last updated: March 9, 2026

What is FETZIMA ER?

FETZIMA ER (levomilnacipran extended-release) is an SNRI approved for the treatment of major depressive disorder (MDD) in adults. Approved by the FDA in July 2013, it offers a differentiated profile within the antidepressant segment due to its dosing and mechanism of action targeting both serotonin and norepinephrine reuptake.

Market Overview

Market size and growth trends

The global antidepressant market was valued at approximately USD 15 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 3.5% through 2028 (Grand View Research, 2022). Major drivers include increased awareness of mental health, rising depression prevalence, and expanding access to healthcare. FETZIMA ER specifically targets a niche within this market, with its unique formulation and dosing profile.

Competitor landscape

Key competitors include:

Drug	Class	Approvals	Peak sales (2021)	Unique features
Effexor XR	SNRI	1993	USD 2.2 billion	Non-selective SNRI, multiple indications
Sertraline	SSRI	1991	USD 3.3 billion	Leading SSRI, broad indication coverage
Duloxetine	SNRI	2004	USD 1.2 billion	Also approved for neuropathic pain
Vilazodone	SSRI/5-HT1Apartial agonist	2011	Data limited	1st in its class
LEVOMILNACIPRAN	SNRI	2013	N/A	Specific to MDD, alternative dosage

Market positioning of FETZIMA ER

FETZIMA ER's approval in 2013 positioned it as a treatment with potentially fewer side effects than older SNRI formulations. Its extended-release profile supports once-daily dosing, which appeals to adherence factors.

Market penetration and adoption

Since launch, FETZIMA ER has captured less than 2% of the antidepressant market share. Adoption varies across regions due to prescriber familiarity, insurance coverage, and formulary placement.

Price Analysis

Current pricing data

• Average wholesale price (AWP): Approximately USD 430 per month for a typical dosing regimen (20 mg or 40 mg daily).
• Estimated out-of-pocket costs: USD 20–USD 50 per month, depending on insurance and discounts.

Price comparison

Drug	Monthly Wholesale Price	Indications	Dosing Frequency
FETZIMA ER	USD 430	MDD	Once daily
Effexor XR	USD 200–USD 400	Anxiety, depression	Once daily
Sertraline	USD 15–USD 50	Depression, OCD, PTSD	Once daily
Duloxetine	USD 200–USD 300	Depression, neuropathy	Once daily

FETZIMA ER's price aligns with other newer SNRI drugs but exceeds the cost of generics like sertraline, affecting market uptake.

Pricing outlook

• Short-term (1–2 years): Expect minor fluctuations influenced by payer negotiations and volume discounts. Target list price likely remains near USD 430.
• Mid-term (3–5 years): Price erosion may occur due to increased generic competition for SNRIs, especially if patents expire or biosimilar options emerge.
• Long-term (5+ years): Potential price decrease of 20–30% driven by generics and market penetration strategies.

Regulatory and Patent Considerations

• Patent protection: U.S. patent expiring in 2027, with potential for extensions.
• Orphan drug status: Not applicable.
• Biosimilar and generic threats: Generics are unlikely due to chemical complexity but could emerge through biosimilar pathways or reformulations.

Market Drivers and Barriers

Drivers

• Rising prevalence of depression.
• Increasing recognition of the importance of adherence.
• Physician interest in personalized treatment profiles.

Barriers

• Dominance of established drugs like sertraline and venlafaxine.
• High cost relative to generics.
• Limited physician familiarity compared to older medications.

Sales and Revenue Projections

Assuming limited market share growth:

Year	Estimated US Sales (USD millions)	Assumptions
2023	USD 30–50	Stable market penetration, price kept steady
2025	USD 50–75	Slight growth as awareness increases
2028	USD 75–100	Market penetration reaches ~5–7% of SNRI sales

Europe and other markets are expected to contribute an additional USD 10–20 million by 2028, contingent on regulatory approval and market access.

Key Takeaways

• FETZIMA ER entered a competitive landscape dominated by older, more affordable SNRIs.
• Current pricing reflects differentiation but limits adoption.
• Patent protection extends into the late 2020s, constraining generic competition.
• Growth relies on prescriber education, formulary positioning, and expanding indications.
• Price erosion is inevitable as generic options increase.

FAQs

1. What are the main competitive advantages of FETZIMA ER?
   Its once-daily extended-release formulation and targeted mechanism can improve adherence and offer a side effect profile distinct from older SNRIs.

2. How does FETZIMA ER's price compare to other antidepressants?
   It costs significantly more than generic SSRIs like sertraline but is comparable to newer SNRI agents.

3. What factors could accelerate FETZIMA ER's market growth?
   Increased prescribing in treatment-resistant depression, expanded indications, and formulary inclusion.

4. When might patents expire, leading to generic competition?
   Patent expiration is projected around 2027, potentially opening the market to generics thereafter.

5. What is the outlook for FETZIMA ER in international markets?
   Limited data suggest gradual expansion, dependent on regulatory approval and local market dynamics.

---

References

[1] Grand View Research. (2022). Antidepressant drugs market size, share & trends analysis report.
[2] U.S. Food and Drug Administration. (2013). FETZIMA (levomilnacipran) extended-release capsules approval letter.
[3] IQVIA. (2022). Medicinal market insights report.